TRANSLATE BIO, INC. Stock Price, News & Analysis

Telesis Bio Inc. (NASDAQ: TBIO) announced that CEO Todd R. Nelson, PhD, will participate in a fireside chat at the 43rd Annual Cowen Healthcare Conference on March 6 at 12:50 PM ET and a panel on Synthetic Biology Enabling Technologies on March 7 at 4:40 PM ET. Both events will be available for live webcast via the company's investor relations website. Telesis Bio, based in San Diego, provides innovative solutions in synthetic biology, including the BioXp® system and the Gibson Assembly® method, facilitating rapid and accurate DNA and mRNA synthesis for various applications in medicine and research. More details can be found on their website.

Telesis Bio (NASDAQ: TBIO) announced the release of its BioXp® Select mRNA Synthesis Kit, allowing scientists to automate mRNA synthesis from their own plasmid DNA. This innovation enables researchers to acquire mRNA in days instead of weeks, enhancing drug discovery efforts in oncology and infectious disease vaccine development. The kit is the second in Telesis Bio's mRNA synthesis product line, following the initial launch last year. The company plans to expand its BioXp® product offerings throughout 2023, increasing flexibility and user adoption.

Frazier Healthcare Partners announced the closing of Frazier Life Sciences Public Fund, raising nearly $830 million in an oversubscribed fund. This marks Frazier's first dedicated public life sciences fund, increasing total capital raised to over $7.1 billion. The fund targets investments in small- and mid-cap public biotech firms. Recent successful exits include Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO), and Trillium Therapeutics (pending acquisition by Pfizer).

On September 8, 2021, Translate Bio (Nasdaq: TBIO) announced the grant of 54,078 restricted stock units to twenty new employees under its 2021 Inducement Stock Incentive Plan. This decision, approved by the compensation committee, serves as an employment inducement and complies with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting by September 8, 2022, and the remainder in thirty-six monthly installments, contingent on continued employment. Translate Bio focuses on mRNA therapeutics, particularly for pulmonary diseases.

Translate Bio has entered a definitive agreement for Sanofi to acquire all its outstanding shares, enhancing mRNA technology deployment in vaccines and therapeutics. Notably, the collaboration has advanced mRNA vaccine programs, including a Phase 1 influenza clinical trial and positive preclinical data for cystic fibrosis and primary ciliary dyskinesia therapeutics. For Q2 2021, Translate Bio reported a net income of $17.1 million, a significant turnaround from a net loss of $36.3 million in the same period last year, with collaboration revenue of $72.6 million.

Sanofi has announced a definitive agreement to acquire Translate Bio for $38.00 per share, totaling approximately $3.2 billion. This acquisition aims to enhance Sanofi's capabilities in mRNA technology, particularly in developing vaccines and therapeutics for various diseases. The deal is supported by commitments from Translate Bio's CEO and its largest shareholder, representing 30% of outstanding shares. The tender offer is expected to commence shortly, with closing anticipated in Q3 2021, subject to standard regulatory approvals and other customary conditions.

On July 6, 2021, Translate Bio (Nasdaq: TBIO) granted non-qualified stock options for 177,400 shares to nine new employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $28.60 per share, matching the closing stock price on the grant date, and vest over four years. Translate Bio is focused on developing mRNA therapeutics, especially for pulmonary diseases like cystic fibrosis, and is exploring a range of treatments including mRNA vaccines through a collaboration with Sanofi Pasteur.

Translate Bio has commenced a Phase 1 clinical trial for their mRNA-based influenza vaccine, in collaboration with Sanofi Pasteur. This trial aims to assess the safety and immune response of the monovalent vaccine targeting the A/H3N2 strain, particularly important for at-risk populations. Promising preclinical results have led to this advancement, with interim data expected by the end of 2021. The partnership focuses on leveraging mRNA technology for vaccine development to enhance flu protection and potentially extend to other diseases.

Translate Bio (Nasdaq: TBIO) announced the granting of non-qualified stock options for 238,200 shares to fifteen new employees, effective June 7, 2021. This initiative is part of the 2021 Inducement Stock Incentive Plan and aims to attract talent. The options have an exercise price of $19.12, aligned with the stock's closing price on the grant date. Vested over four years, these options require continued employment for vesting. Translate Bio focuses on mRNA therapeutics, especially for pulmonary diseases like cystic fibrosis and is collaborating on mRNA vaccines with Sanofi Pasteur.